Nebulized Morphine in Chest Trauma Patients: A Prospective Study
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT03580187 |
|
Recruitment Status :
Completed
First Posted : July 9, 2018
Last Update Posted : September 23, 2022
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
| Condition or disease | Intervention/treatment | Phase |
|---|---|---|
| Blunt Injury of Thorax | Drug: Morphine (+) | Phase 3 |
The aim of this study was to determine the predictive factors of nebulized morphine failure in patients with chest trauma and to establish a score based on these factors to guide the analgesic protocol.
Methods: This is a prospective study carried out from 2018 to 2020 including patients aged ≥ 18 years, admitted for isolated chest trauma. Each patient received a nebulization of 10 mg morphine. If Visual Analog Score (VAS) assessed after 10 minutes still> 4, nebulization was repeated every 10 minutes until pain relief. At 30 minutes, VAS> 4 means failure.
| Study Type : | Interventional (Clinical Trial) |
| Actual Enrollment : | 75 participants |
| Allocation: | N/A |
| Intervention Model: | Single Group Assignment |
| Intervention Model Description: | Were included all patients aged 18 years and over, victims of isolated chest trauma, who were admitted to the intensive care unit. We excluded patients with any of the following criteria: not consent, pregnant woman, polytrauma, hemodynamic instability with systolic blood pressure less than 100 mmHg, treatment with morphine during transport or in the emergency room, need for initial ventilatory support, bradypnea (respiratory rate less than 12 cycles per minute), allergy to opiods, initial pain Visual Analog Scale (VAS) ≤ 4. Pain level was assessed by the pain VAS. We collected demographic, epidemiological, initial clinical examination data, explorations, lesions and we monitored the evolution of the VAS and the vital signs. Informed consent was obtained from all patients |
| Masking: | None (Open Label) |
| Primary Purpose: | Treatment |
| Official Title: | Nebulized Morphine in Chest Trauma Patients: A Prospective Study |
| Actual Study Start Date : | June 14, 2018 |
| Actual Primary Completion Date : | April 15, 2020 |
| Actual Study Completion Date : | April 15, 2020 |
| Arm | Intervention/treatment |
|---|---|
|
morphine +
We performed a first nebulization of 10 mg (1mL) of morphine diluted in 4 mL of normal saline using a nebulizer with an oxygen flow rate of 8 L / min. The quality of analgesia was assessed by VAS at rest and cough after 10 minutes. If ≤ 4, we concluded to a success. If VAS was still> 4, a second nebulization was performed. After 20 minutes, if VAS still higher than 4 we performed a third nebulization. If pain level was ≤ 4, we concluded to a success. morphine (+) group: good response to morphine in nebulization after 30 min if VAS > than 4 we conclude to morhine (-) |
Drug: Morphine (+)
We performed a first nebulization of 10 mg (1mL) of morphine diluted in 4 mL of normal saline using a nebulizer with an oxygen flow rate of 8 L / min. The quality of analgesia was assessed by VAS at rest and cough after 10 minutes. If ≤ 4, we concluded to a success. If VAS was still> 4, a second nebulization was performed. After 20 minutes, if VAS still higher than 4 we performed a third nebulization. If pain level was ≤ 4, we concluded to a success. After 30 minutes, if VAS still> 4, we concluded to a failure of morphine nebulization. The patients were divided into two groups: morphine (+) group: good response to morphine in nebulization morphine (-) group: failure of morphine in nebulization Other Name: morphine (-) |
- analgesia evaluated with visual scale [ Time Frame: 30 minuts ]morphine (+) group: good response to morphine in nebulization morphine (-) group: failure of morphine in nebulization
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
| Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
| Sexes Eligible for Study: | All |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- patients aged 18 years and over
- victims of isolated chest trauma,
- admitted to the intensive care unit
Exclusion Criteria:
- not consen
- pregnant woman
- polytrauma
- hemodynamic instability with systolic blood pressure less than 100 mmHg,
- treated with morphine during transport or in the emergency room
- need initial ventilatory support, bradypnea (respiratory rate less than 12 cycles per minute)
- allergy to opiods
- initial pain Visual Analog Scale (VAS) ≤ 4
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03580187
| Tunisia | |
| Mahdia Hospital | |
| Mahdia, Tunisia, 5180 | |
| Responsible Party: | Majdoub Ali MD, head of anesthesia departement, University Hospital, Mahdia |
| ClinicalTrials.gov Identifier: | NCT03580187 |
| Other Study ID Numbers: |
NMCT/1 |
| First Posted: | July 9, 2018 Key Record Dates |
| Last Update Posted: | September 23, 2022 |
| Last Verified: | September 2022 |
| Individual Participant Data (IPD) Sharing Statement: | |
| Plan to Share IPD: | Undecided |
| Studies a U.S. FDA-regulated Drug Product: | No |
| Studies a U.S. FDA-regulated Device Product: | No |
| Product Manufactured in and Exported from the U.S.: | No |
|
Thoracic Injuries Wounds, Nonpenetrating Wounds and Injuries Morphine Analgesics, Opioid Narcotics |
Central Nervous System Depressants Physiological Effects of Drugs Analgesics Sensory System Agents Peripheral Nervous System Agents |